Objective: Quality-improvement efforts are hindered by a lack of consensus on meaningful and feasible measures of care. The objective of this study was to develop a core set of quality measures for mental health and substance-related care that are meaningful to stakeholders, feasible to implement, and broadly representative of diverse dimensions of the mental health system. Method: A 12-member panel of stakeholders from national organizations evaluated 116 process measures in a 2-stage modified Delphi consensus development process. Drawing on a conceptual framework and literature review, panelists rated each measure on 7 domains using a 9-point scale (1 ϭ best). Measures were then mapped to a framework of system dimensions to identify a core set with the highest ratings for system characteristics within each dimension. Results: Twenty-eight measures were identified assessing treatment (12) , access (2) , assessment (2) , continuity (4), coordination (2) , prevention (1) , and safety (5) . Overall, mean ratings for meaningfulness were: clinical importance 2.29; perceived gap between actual and optimal care 2.59; association between improved performance and outcome 2.61. For feasibility, mean ratings were clarity of specifications 3.39; acceptability of data collection burden 4.77; and adequacy of case mix adjustment 4.20. The measures address a range of treatment modalities, clinical settings, diagnostic categories, vulnerable populations, and other dimensions of mental healthcare. Conclusions: A structured consensus process identified a core set of quality measures that are meaningful and feasible to multiple stakeholders, as well as broadly representative of the mental healthcare system. By yielding quantitative assessments of meaningfulness, feasibility and degree of consensus among stakeholders, these results can inform ongoing national efforts to adopt common quality measures for mental healthcare. 
M
easurement-based quality assessment and quality improvement (QA/QI) activities are underway throughout the US healthcare system. However, there is little agreement among "stakeholders" in the mental healthcare system (eg, consumers, families, clinicians, payers, purchasers, and oversight organizations) on which measures should be used. Lack of agreement on common measures increases the burden of data collection on providers, decreases the comparability of measure results, and slows efforts to test and refine measures with most promise.
The implementation of standardized sets of "core measures" is widely advocated to ensure that systems and providers focus on clinically important processes with known variations in quality of care. [1] [2] [3] [4] Measures typically are selected on the basis of criteria for meaningfulness and feasibility as well as to represent diverse dimensions of the system under evaluation. 5 There are a number of initiatives aimed at developing consensus on quality measures for mental healthcare. 6 -8 Progress has been made for a few settings and conditions. 9 -12 It has proven more difficult to achieve consensus among stakeholders on a broader set of measures that are representative of the diverse conditions, treatments, settings and populations that comprise the mental healthcare system. Among the barriers are, first, existing measures are numerous and vary widely in content and scientific properties. A national inventory identified more than 300 process measures proposed for QA/QI. [13] [14] [15] [16] Less than 40% were based on research evidence. Few were assessed for validity or reliability. They draw on a wide range of data sources, each with implications for feasibility of use. Second, stakeholder groups participating in initiatives to select mental health measures have widely divergent priorities with regard to measure content, rigor and burden. 17 This study addresses the question, how can diverse stakeholders with competing values select quality measures for common use? We developed a method that brought stakeholders from national organizations together to systematically review measures for mental healthcare and identify a core set of 25-30 that were meaningful, feasible, and representative of diverse dimensions of the mental health system. We focused on a specific, widely used type of measuresingle-item, technical process measures-which examine the clinical content of care, usually in comparison with a standard or norm.
Method
Building on prior work in consensus development, 18 -20 we developed a method to select core measures by identifying areas of common interest, balancing competing interests, and providing a floor based on measure quality. First, we developed a framework to identify measure attributes and system dimensions. Second, we screened existing measures to identify promising candidates. Third, we convened a panel of diverse stakeholders to rate candidate measures. Fourth, core measures were selected on the basis of panel ratings and system representativeness.
Conceptual Framework
Broad agreement exists on several principles for quality measurement. 21 Measures should be meaningful, ie, address known quality problems in clinically important areas, be evidence-based and valid, and yield actionable results. Measures should be feasible, ie, precisely specified, reliably collected, adequately case mix adjusted, and based on available and affordable data. Core measure sets should reflect the diversity of systems they are intended to assess. Important dimensions of mental healthcare include different psychiatric conditions, modalities, settings, clinical processes (ie, prevention, access, assessment, treatment, continuity, coordination, and safety), and needs that are specific to vulnerable groups. We developed a conceptual framework that incorporates these principles but also identifies tensions among them. 17 For example, measures based on research evidence often require more costly sources of data and are not equally available across conditions, treatment modalities or groups. 13, 14 In this way, the goal of meaningfulness conflicts with the goals of feasibility and representativeness. The framework identified areas where stakeholder priorities conflict and require tradeoffs to produce consensus.
Measure Collection and Screening
Drawing on a nationwide inventory of technical process measures developed for QA/QI in mental healthcare, 13, 16 we screened available measures for a face relationship to quality, specifications for use and use of existing data sources (Fig. 1 ). This process resulted in 116 measures for review by the panel. Detailed information on the measures and their properties are available at www.cqaimh.org.
Stakeholder Panel Composition
Measure ratings were obtained from a diverse panel of stakeholders using a 2-stage modified-Delphi method. 22 In consultation with national stakeholder organizations, we selected 12 panelists representing each stakeholder perspective (Table 1) . 
Measure Rating Process
Panelists were provided with available information on 116 measures, including specifications, rationales, data requirements, research evidence, reliability and validity results and case mix adjustment. Profiles were developed by research staff based on training and guidelines and were verified by a study investigator. Attributes requiring judgment (eg, evidence) were subject to inter-rater reliability testing with kappa scores of 0.5 (moderate) to 1.0 (excellent). 23 There were 2 rounds of ratings. First, panelists individually rated each measure on 3 scales assessing meaningfulness (importance of the process to the panelist's stakeholder group, perceived gap between actual and optimal care, and perceived relationship between improved performance on the measure and patient outcomes) and 3 scales assessing feasibility (clarity of specifications, acceptability of data collection burden, and capacity to provide fair comparisons across healthcare organizations). A seventh scale assessed, overall, whether the measure should be included in the core set. Responses were obtained on a 9-point Likert scale: 1 to 3 indicating agreement, 4 to 6 neither agreement nor disagreement, and 7 to 9 disagreement. First-round ratings were provided to panelists as a basis for discussion, including the median, distribution and dispersion (mean absolute deviation from the median, indicating degree of agreement). Discussion focused on measures with overall scores of 6 or less and significant dispersion. If consensus for revision existed, the panel made changes for content or clarity. After discussion, panelists rerated each measure individually and confidentially.
Analysis
Meaningfulness and feasibility ratings were calculated for each measure as the mean result from the 3 scales comprising each domain. Mean ratings across measures were calculated after the first and second rounds of rating and for the final core set. To explore differences among stakeholders, we grouped panelists by perspective: managers/oversight (5 panelists); clinicians/consumers (4); and researchers/evaluators (3). Sample sizes were insufficient to examine the statistical significance of these comparisons.
Core Set Construction
A preliminary core set was selected on the basis of final measure scores. We set thresholds for meaningfulness of 3 or less with dispersion of 0.8 or less, and feasibility of 6 or less with dispersion 0.9 or less. The threshold for feasibility was lower because measures can often be improved by revising specifications.
To balance goals of measure quality and system representativeness, characteristics of the preliminary set were compared with mental health system dimensions described in the framework. To address areas that the panel identified as a priority but not represented in the preliminary set (eg, racial/ ethnic disparities), the highest-rated measure in that category was added to the core set.
Results
First-round ratings of 116 measures showed better scores and more agreement for meaningfulness than for feasibility. In the second round, 39 measures with potentially acceptable scores but poor agreement were discussed by the panel and rerated. Agreement on these measures improved after discussion, with the average dispersion in the overall score declining from 1.39 in the first round to 0.93 in the second. Mean ratings of meaningfulness were similar across the 3 broader stakeholder groups (range: 2.89 -3.07). Greater divergence was seen on feasibility, with clinicians/consumers (3.82) more likely to rate measures as feasible than managers/ oversight (5.09) or researchers/evaluators (4.49).
No. Panelists
Twenty-one measures met thresholds for inclusion in the preliminary set. Seven additional measures were added as the most highly rated in unrepresented priority areas. Table 2 presents the 28 measures comprising the final core set. 24 -45 Mean panelist ratings (dispersion) of the meaningfulness of the set were clinical importance 2.29 (0.61); perceived gap between actual and optimal care 2.59 (0.76); and association between improved performance and outcome 2.61 (0.79). Feasibility ratings were clarity of specifications 3.39 (1.13); acceptability of data collection burden, 4.77 (1.21); and adequacy of case mix adjustment 4.20 (1.16) .
With regard to the goal of representativeness, the core measures address a range of priorities across system dimensions. Of 28 measures, 12 assess treatment, 5 safety, 4 continuity, 2 access, 2 assessment, 2 coordination, and 1 prevention. Fifteen measures assess care for specific disorders: depression (4), schizophrenia (5), substance abuse/ dependence (1), dementia (2), bipolar disorder (1), borderline personality disorder (1), and dual diagnosis (1). Four measures assess psychosocial interventions, 8 assess pharmacotherapy, and 2 address medical care for psychiatric patients. Settings assessed include outpatient, inpatient, residential, emergency, nursing home, and primary care. Measures addressed care for children (5) , elderly patients (4), and racial/ ethnic minorities (1) .
Nearly all the core set measures (93%) require administrative data; 61% require data from additional sources. Sixteen measures (57%) evaluate clinical processes based on research evidence: 4 supported by randomized controlled trials and 12 by less-rigorous research.
The panel assessed readmission and ambulatory follow-up rates after hospital discharge based on commonly used intervals of 7, 14, 30, and 90 days. The panel rated the 7-day interval as most meaningful for each measure. Only the ambulatory follow-up measure met inclusion thresholds for the core set.
Discussion
We applied a method of consensus developmentincorporating stakeholder values, research data, and a means of identifying agreement while permitting trade-offs among competing priorities-to identify a core set of 28 quality measures for mental healthcare. To what extent did this core set reach the desired goals of representation, meaningfulness, and feasibility?
Breadth of representation was achieved in several dimensions. The core set includes measures addressing each process domain, 8 diagnostic categories, biologic and psychosocial treatments, numerous levels of care, and clinical needs specific to several vulnerable groups.
With regard to meaningfulness, all 28 measures had scores in the "agreement" range. However, nearly half lacked supporting research evidence, and only 4 were supported by randomized controlled trials. This reflects the current state of measure development and an evidence base for mental healthcare that is narrow relative to the diverse circumstances encountered in practice.
On average, the feasibility of the core measures was rated worse than meaningfulness. In part this results from limited methods of case-mix adjustment for mental healthcare. 46 It also stems from concerns about the burden of data collection-the subject of greatest disagreement among panelists. Panelists from the manager/oversight groups (typically responsible for collecting data), rated measures as more burdensome than either consumers/clinicians or researchers/ evaluators. Several national QA initiatives use only measures using administrative data because of the costs of medical record abstraction and administering surveys. Our results suggest that a broader array of data sources are needed to produce a set of measures that are meaningful, feasible, and diversely representative. This conclusion is consistent with the Institute of Medicine's determination that a "mosaic of data sources" are needed to meet national quality-assessment needs. 5 Achieving consensus on core quality measures presents a significant challenge, particularly in mental health care, where multiple clinical disciplines, an influential consumer movement, and a specialized managed behavioral healthcare industry bring diverse perspectives to the table. Both the method described in this report and the resulting measures may be useful to policy groups working toward standardized measures, including the Forum on Performance Measures in Behavioral Health and the National Quality Forum. The Delphi method permits identification of measures representing priorities of diverse stakeholders without requiring them to agree on each measure. Mapping ratings of measure attributes to priority system dimensions allows for balance between these considerations. The measures reported here, having been vetted by diverse stakeholders, may achieve greater acceptance and use in activities to improve care.
Our process identified gaps where further measure development is needed, including assessment of children, recovery-oriented treatment, racial and ethnic disparities, and care for posttraumatic stress disorder, developmental disorders, and mental retardation.
A limitation of Delphi processes is that few participants represent any one perspective. We sought to enhance reproducibility by selecting panelists belonging to national organizations that have well-established perspectives on quality measurement. A costly alternative would have been to conduct multiple panels and assess their reliability. Another approach, surveying stakeholders, would have allowed for a larger sample but without an exchange of views. Our decision to restrict this study to a single, widely used type of measure should not be interpreted as advocating for process measures over other approaches to assessment. Multiple perspectives are essential to understanding qualityincluding measures of outcome, satisfaction, interpersonal process and fidelity to evidence-based treatment models. The strengths and weaknesses of these approaches complement one another and, collectively, provide a more robust armamentarium for improving quality of care. 47 Resources for improving quality are limited, and measures used in national core sets will likely influence where funds are spent. These measures should thus be chosen wisely. Some of the information needed to inform their selection (eg, validity) may come only after implementation in large samples and analysis of results. This speaks to the need for an iterative process of selection and implementation that may initially rely on consensus but incorporates empirical information as it becomes available. Administrative data, medical record C *Meaningfulness ratings were calculated as the average of measure scores on 3 scales: clinical importance, perceived gap between actual and optimal care, and association between improved performance and outcome.
† Feasibility ratings were calculated as the average of measure scores on 3 scales: clarity of specifications, acceptability of data collection, and adequacy of case-mix adjustment.
‡ AHRQ rating categories were used to assess the research evidence supporting the association between the underlying clinical process and patient outcomes: A) good research evidence such as well-designed randomized controlled trials; B) fair research-based evidence such as retrospective analyses of observational data; C) no research evidence, principally clinical consensus or opinion. 45 § Denotes that the measure was modified during the core set development process and differs from the specifications in the cited reference. Beneficiaries can refer to insurance program enrollees or to populations, as in the case of public sector programs.
